SAR629 is primarily utilized in the field of oncology research, where it is investigated for its potential as a therapeutic agent targeting specific cancer pathways. It is studied for its ability to inhibit certain proteins or enzymes that are crucial for the survival and proliferation of cancer cells. Researchers are particularly interested in its application in preclinical models to assess its efficacy, safety, and mechanism of action in various types of cancers. Additionally, SAR629 is explored in combination therapies to enhance the effectiveness of existing treatments or to overcome resistance mechanisms in cancer cells. Its development and application contribute to advancing personalized medicine approaches in cancer treatment.